Publication

Intérêt sur la survie globale à 5 ans de l'ajout dans le suivi d’une mesure du taux d'ACE et/ou d’une imagerie par scanner pour la surveillance des cancers du rectum opérés à visée curative

ANNÉE

2023

AUTEURS

Phelip JM

CONGRÈS/REVUE

JFHOD

Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients: Results from the PETACC 8 study

ANNÉE

2023

AUTEURS

Bergen E

CONGRÈS/REVUE

ESMO

LIEN PUBLICATIONS ASSOCIÉES

https://oncologypro.esmo.org/meeting-resources/esmo-congress/impact-of-concomitant-medication-on-recurrence-survival-and-tolerability-of-chemotherapy-in-early-colon-cancer-patients-results-from-the-petacc-8

PREDICTIVE MODELS OF RECURRENCE FROM TRANSCRIPTOMIC SIGNATURES OF THE TUMOR MICROENVIRONMENT AND CELL CYCLE IN STAGE III COLON CANCER FROM PETACC-8 AND IDEA-FRANCE TRIALS

ANNÉE

2023

AUTEURS

Gallois C

CONGRÈS/REVUE

ASCO

Improved colorectal cancer survival prediction with deep learning-based WSI analysis

ANNÉE

2023

AUTEURS

OKWIN

CONGRÈS/REVUE

AACR

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial

ANNÉE

2022

AUTEURS

de Rauglaudre B, Sibertin-Blanc C, Fabre A, Le Malicot K, Bennouna J, Ghiringhelli F, Taïeb J, Boige V, Bouché O, Chatellier T, Faroux R, François E, Jacquot S, Genet D, Mulot C, Olschwang S, Seitz JF, Aparicio T, Dahan L

CONGRÈS/REVUE

Ther Adv Med Oncol

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1177/17588359221141307

A randomized, non-comparative, phase II study of maintenance OSE2101 vaccine alone or in combination with nivolumab (nivo) or FOLFIRI after induction with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): First interim results of the TEDOPAM GERCOR D17-01 PRODIGE 63 STUDY.

ANNÉE

2022

AUTEURS

Hilmi M, Mitry E, Turpin A, Bouché 0, Metges JP, Ghiringhelli F, Trouilloud I, Roth G, Baumgaertner I, Borg C, Ammarguellat H, Guillet M, Rinaldi Y, Lecomte T, Louvet C, Lambert A, Hautefeuille V, Garcia-Larnicol ML, Henriques J , Neuzillet C

CONGRÈS/REVUE

ASCO

LIEN PUBLICATIONS ASSOCIÉES

https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4148

A randomized non-comparative phase II study of maintenance OSE2101 vaccine alone or in combination with nivolumab (nivo), or FOLFIRI after induction with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): first interim results of the TEDOPAM GERCOR D17-01 PRODIGE 63 STUDY.

ANNÉE

2022

AUTEURS

Hilmi M, Mitry E, Turpin A, Bouché 0, Metges JP, Ghiringhelli F, Trouilloud I, Roth G, Baumgaertner I, Borg C, Ammarguellat H, Guillet M, Rinaldi Y, Lecomte T, Louvet C, Lambert A, Hautefeuille V, Garcia-Larnicol ML, Henriques J , Neuzillet C

CONGRÈS/REVUE

ASCO

LIEN PUBLICATIONS ASSOCIÉES

https://meetings.asco.org/abstracts-presentations/210687/poster

Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma. A SCARCE-PRODIGE 60 randomized phase II study

ANNÉE

2022

AUTEURS

Kim S, Ghiringhelli F, De La Fouchardiere C,Francois E, Smith MD, Samalin E, Lopez-Trabada Ataz D, Parzy A, Desrame J, Baba-Hamed N, Buecher B, Tougeron D, Bouché O, Chibaudel B, El Hajbi F, Garcia-Larnicol ML, Meurisse A, Vernerey D, Pernot S, Borg C

CONGRÈS/REVUE

ASCO

LIEN PUBLICATIONS ASSOCIÉES

https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3508

PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

ANNÉE

2022

AUTEURS

Tougeron D, Dahan L, El Hajbi F, KLe Malico K, Evesque L, Aparicio T, Bouche O, Bonichon Lamichhane N, Chibaudel B, Angelergues A, bodere A, Phelip JM, Mabro M, Artru P, Louvet C

CONGRÈS/REVUE

ESMO

LIEN PUBLICATIONS ASSOCIÉES

https://oncologypro.esmo.org/meeting-resources/esmo-congress/prodige-59-durigast-trial-a-randomised-phase-ii-study-evaluating-folfiri-plus-durvalumab-and-folfiri-plus-durvalumab-plus-tremelimumab-in-second

PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus Durvalumab and FOLFIRI plus Durvalumab plus Tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.

ANNÉE

2022

AUTEURS

Tougeron D, Dahan L, El Hajbi F, KLe Malico K, Evesque L, Aparicio T, Bouche O, Bonichon Lamichhane N, Chibaudel B, Angelergues A, bodere A, Phelip JM, Mabro M, Artru P, Louvet C

CONGRÈS/REVUE

ASCO

LIEN PUBLICATIONS ASSOCIÉES

https://ffcd.fr/images/Publications/2022/ASCO%202022%20DURIGAST%20v2.pdf